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Abstract
Transforming growth factor-L1 (TGF-L1), an abundant growth factor in bone matrix, has been shown to be involved in
bone formation and fracture healing. The mechanism of action of the osteogenic effect of TGF-L1 is not clearly understood.
In this study, we found that the addition of TGF-L1 to murine osteoblastic MC3T3-E1 cells induced vascular endothelial
growth factor (VEGF) mRNA production. VEGF mRNA levels reached a plateau within 2 h after the addition of TGF-L1.
The induction was superinduced by cycloheximide and blocked by actinomycin D. Ro 31-8220, a protein kinase C inhibitor,
abrogated the induction. In addition, curcumin, an inhibitor for transcription factor AP-1, also blocked the induction.
Electrophoretic mobility shift assay revealed an enhanced binding of transcription factors AP-1 and NF-UB. Transient
transfection experiment showed that VEGF promoter activity increased 3.6-fold upon TGF-L1 stimulation. Immunoblot
analysis showed that the amount of secreted VEGF was elevated in the medium 4 h after TGF-L1 stimulation. Our results
therefore suggest that at least part of the osteogenic activity of TGF-L1 may be attributed to the production of
VEGF. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Transforming growth factor-L1 (TGF-L1) is a ho-
modimeric protein with autocrine and paracrine ac-
tivities found in a variety of cell types [1]. TGF-L1,
-L2 and -L3 are di¡erentially expressed in mamma-
lian tissues. In bone, TGF-L1 and -L2 are produced
by osteoblasts and incorporated into mineralized
bone matrix [2,3]. TGF-L1 stimulates matrix forma-
tion including ¢bronectin, collagen, osteonectin, and
integrins [4,5]. Administration of TGF-L has been
reported to enhance cancellous bone formation in
juvenile and adult rat bone [6] and fracture healing
[7,8]. However, the cascade of events that leads to
bone formation and repair by TGF-L1 is not clear at
present.
Bone, especially trabecular bone, is rich in vascular
tissues. Endothelial cells lining the bone are in close
proximity with osteoblasts and osteoprogenitor cells
[9,10]. These endothelial cells secrete various cyto-
kines, growth factors or soluble mediators that are
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crucial for bone remodeling and formation. Vascular
endothelial growth factor (VEGF) plays an impor-
tant role in bone metabolism and a¡ects both osteo-
blasts and osteoclasts. In rat osteoblasts, prostaglan-
din E2 and E1 could induce VEGF at both mRNA
and protein level [11]. The expression of VEGF
mRNA in primary murine osteoblasts is increased
by insulin-like growth factor-1 [12]. Calciotropic hor-
mones upregulate VEGF in osteoblast-like cells
[13,14]. VEGF also regulates osteoblast di¡erentia-
tion: when added to fetal bovine osteoblasts, it in-
duces their migration, PTH-dependent cAMP accu-
mulation and alkaline phosphatase increase [15].
VEGF also induces osteoclast recruitment in bones
of osteopetrotic mice [16]. Hypoxia regulates the ex-
pression of VEGF in osteoblast-like cells in a dose-
dependent fashion [17]. Finally, osteogenic protein-1,
which is known to stimulate new bone formation in
vivo and to induce cell proliferation and di¡erentia-
tion of osteoblasts in vitro, has been shown to in-
crease the steady-state level of VEGF mRNA in a
dose- and time-dependent manner [18]. The purpose
of the present study was to determine whether TGF-
L1 a¡ects bone metabolism through the production
of VEGF by the osteoblasts.
VEGF is a heparin-binding, homodimeric protein
of 45 kDa [19^21]. Several forms of human VEGF
exist as a result of alternative splicing: VEGF 121,
165, 189, and 206 [22,23]. Murine VEGFs are one
amino acid shorter than those of humans [24].
Whereas VEGF 121 and VEGF 165 are secreted
into the bloodstream, VEGF 189 and VEGF 206
are sequestered in the cell matrix or bound to cell
membranes [25]. It is important for normal cell
growth, development, di¡erentiation, wound healing
and reproduction.
In this study, we report that TGF-L1 could up-
regulate VEGF transcripts in murine osteoblastic
MC3T3-E1 cells. The induction was due to transcrip-
tional activation. The secreted VEGF level was also
elevated after TGF-L1 treatment. Our results suggest
that VEGF may contribute to the osteogenic e¡ect of
TGF-L1.
2. Materials and methods
2.1. Cell culture and materials
Murine osteoblast MC3T3-E1 cells [26] were cul-
tured in K-modi¢ed MEM (Sigma) containing 10%
fetal bovine serum (FBS), 2 mM L-glutamine and 25
Wg/ml gentamicin at 37‡C in a humidi¢ed atmosphere
of 5% CO2. Cells were serially subcultured by treat-
ment with trypsin (0.05% trypsin in 0.5 mM Versene)
and were used for experimentation between passages
4 and 10. Human recombinant TGF-L1 was pur-
chased from RpD Systems (Minneapolis, MN). Cur-
cumin, polydI^polydC, and salmon testes DNA were
obtained from Sigma. Ro 31-8220 was obtained from
Calbiochem-Novabiochem (San Diego, CA). [K-
32P]dCTP and [Q-32P]ATP were obtained from ICN
(Costa Mesa, CA). Fetal bovine serum was obtained
from Bio£uids (Bethesda, MD). Anti-human VEGF
antibody was purchased from Peprotech (Rocky Hill,
NJ). T4 polynucleotide kinase, luciferase assay kit,
DNA size marker, AP-1 and NF-UB consensus olig-
omers were purchased from Promega (Madison, WI).
RT-PCR kit was obtained from Perkin-Elmer Cetus
(Foster City, CA). FuGene 6 transfection reagent
was obtained from Boehringer Mannheim (Indianap-
olis, IN). ECL reagent was purchased from Amer-
sham Pharmacia Biotech (Piscataway, NJ). All other
reagents used were of the highest grade commercially
available.
2.2. Northern blot analysis
Cells were seeded into 100-mm dishes containing
K-MEM and 10% FBS. Near con£uent cells were
changed to K-MEM containing 0.5% FBS for 16 h
before the addition of test agents. After designated
time, total RNA was extracted using the acid guani-
dinium thiocyanate^phenol^CHCl3 extraction meth-
od [27]. Fifteen micrograms of RNA was denatured
and separated by electrophoresis on 1% agarose gel
containing 2.2 M formaldehyde. Following transfer,
the RNA was covalently bound to GeneScreen by
UV-crosslinking. Hybridization and washing condi-
tions were carried out according to the method of
Church and Gilbert [28]. A human VEGF cDNA
probe was provided by Dr. Donald Torry (Univer-
sity of Tennessee, Knoxville). The cDNA was labeled
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with [32P]dCTP using random primer labeling. The
blots were exposed to XAR ¢lms with intensifying
screens. The intensity of the bands was quantitated
by Digital Imaging System (Alpha Innotech). Experi-
ments were repeated at least three times, and repre-
sentative data are shown.
2.3. RT-PCR analysis of VEGF transcripts
Total RNA isolated from MC3T3-E1 cells was
treated with DNase I. The cDNA was synthesized
by reverse transcription reaction of 5 Wg of RNA.
Five Wl of cDNA was ampli¢ed by Taq DNA poly-
merase in a 25-Wl reaction containing 10 mM Tris-
HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM
dNTP, and 10 pmol of the two primers: (1) 5P-TG-
CGATGCGGGGGCTGC-3P (sense); and (2) 5P-TT-
TCCTGGTGAGAGTCT-3P (antisense).
The PCR reaction was allowed to proceed for 40
cycles, each cycle consisting of 45 s at 94‡C, 35 s at
54‡C, 45 s of polymerization at 72‡C and ¢nally a
10-min extension at 72‡C. Aliquots of 10 Wl of the
PCR product were separated on a 2.5% agarose gel.
A 100-bp DNA ladder was included as a size marker.
2.4. VEGF promoter activity
MC3T3-E1 cells in 60-mm dishes were transfected
with 2 Wg promoterless luciferase gene (pxp2) or a
luciferase gene-containing VEGF promoter (1.6 kb
EcoRV^PstI sequence, gift of Drs. Andrew P. Levy
and Mark A. Goldberg, Harvard Medical School)
[29] in the presence of 5 Wl FuGene 6 according to
the manufacturer’s protocol. After 5 h, the cells were
changed to K-MEM containing 10% FBS overnight.
The cells were then incubated in serum-free medium
containing 10 ng/ml TGF-L1 for 36 h. Cultures were
incubated with lysis bu¡er and luciferase activity in
the lysate was measured with a kit from Promega.
2.5. Nuclear extract and electrophoretic mobility shift
assay
Nuclear extracts from control and TGF-L1-treated
cells were prepared according to Andrews and Faller
[30]. AP-1 and NF-UB consensus sequences were end-
labeled with [Q-32P]ATP and T4 kinase. Binding re-
action (20 Wl) containing 10 Wg of nuclear extract, 1
Wg testes DNA, and 1 Wg polydI^polydC was prein-
cubated at room temperature with or without 100-
fold excess of unlabeled oligomers as competitors for
15 min. 32P-Labeled AP-1 or NF-UB (20 000 cpm)
was then added to the reaction and incubated at
room temperature for another 20 min. The samples
were resolved on native 4% polyacrylamide gel at
4‡C with 0.5UTBE. The gel was dried and analyzed
by autoradiography.
2.6. Immunoblot analysis of VEGF
Near con£uent MC3T3-E1 cultures in 100-mm
dishes were incubated with K-MEM supplemented
with 0.5% FBS. Cells were treated with or without
TGF-L1 for designated times. Conditioned media
were collected in the presence of protease inhibitors
(2 Wg/ml aprotinin, 2 Wg/ml leupeptin and 0.5 mM
phenylmethylsulfonyl £uoride). Secreted proteins in
the conditioned medium were precipitated with qui-
nine sulfate^SDS as described previously [31]. The
precipitates were resuspended in Laemmli SDS gel
sample bu¡er and electrophoresed on 10% SDS^
PAGE. Immunoblots were carried out with rabbit
anti-human VEGF antibodies (1:500) at room tem-
perature for 1.5 h and then with goat anti-rabbit IgG
conjugated to HRP (1:10 000, Sigma) for 1 h. Chem-
iluminescence was detected using ECL reagent.
3. Results
Steady-state levels of VEGF mRNA were deter-
mined in MC3T3-E1 cultures by Northern blot anal-
ysis. The basal level of VEGF mRNA (3.7 kb) was
low. The mRNA level increased rapidly upon the
addition of TGF-L1. Levels of VEGF mRNA in-
creased 3.4-fold at 2 h (Fig. 1, lane 4) and then
declined. As shown in Fig. 2, VEGF mRNA re-
sponded to TGF-L1 in a dose-dependent manner.
The next series of experiments was performed to
examine the mechanism of VEGF mRNA induction.
Inhibitors of protein and RNA synthesis were in-
cluded singly or in combination with TGF-L1. Cyclo-
heximide alone minimally induced VEGF mRNA
(Fig. 3, lane 3). In the presence of TGF-L1 and cy-
cloheximide (lane 4), the induction was higher than
TGF-L1 alone (lane 2), implying that the induction
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does not require de novo protein synthesis. In the
presence of actinomycin D, the induction was abol-
ished (lane 6), indicating that de novo RNA synthe-
sis is required.
We next investigated whether TGF-L1 exerted its
e¡ect through a protein kinase C (PKC)-dependent
pathway. Ro 31-8220, a PKC inhibitor [32], was in-
cluded in our experiment. Cells were pretreated with
15 WM Ro 31-8220 for 30 min prior to the addition
of TGF-L1. Ro 31-8220 was able to block the induc-
tion of VEGF mRNA (Fig. 4, lane 4). Our results
suggest that the e¡ect of TGF-L1 is mediated by a
PKC-dependent pathway. The promoter of the
mouse VEGF gene has been shown to contain AP-
Fig. 4. E¡ect of a protein kinase C inhibitor, Ro 31-8220, on
the induction of VEGF mRNA by TGF-L1. Near con£uent
MC3T3-E1 cells were pretreated with 15 WM Ro 31-8220 for 30
min before the addition of 5 ng/ml TGF-L1 for 2 h. Hybridiza-
tion patterns of control cells (lane 1); cells treated with TGF-
L1 (lane 2); Ro 31-8220 (lane 3); TGF-L1 and Ro 31-8220
(lane 4); are shown.
Fig. 3. E¡ect of cycloheximide (CHX) and actinomycin D (Act
D) on the induction of VEGF mRNA by TGF-L1. Near con-
£uent cultures of MC3T3-E1 cells were treated with 5 ng/ml
TGF-L1 for 2 h in the absence or presence of CHX (20 Wg/ml)
or Act D (1 Wg/ml). Fifteen Wg of total RNA was hybridized
with a human VEGF cDNA probe. Hybridization patterns of
control cells (lane 1); cells treated with TGF-L1 (lane 2); CHX
(lane 3); TGF-L1 and CHX (lane 4); Act D (lane 5); TGF-L1
and Act D (lane 6); are shown.
Fig. 2. Dose-dependent induction of VEGF mRNA by TGF-
L1. Near con£uent cultures of MC3T3-E1 cells were treated
with di¡erent concentrations of TGF-L1 for 2 h. Fifteen Wg of
total RNA was hybridized with a cDNA probe for human
VEGF. Hybridization patterns of control cells (lane 1); cells
treated with 1 ng/ml TGF-L1 (lane 2); 5 ng/ml TGF-L1 (lane
3); 10 ng/ml TGF-L1 (lane 4); 25 ng/ml TGF-L1 (lane 5); are
shown.
Fig. 1. Time course of VEGF mRNA induction in MC3T3-E1
cells by TGF-L1. Near con£uent cultures were exposed to 5 ng/
ml TGF-L1 for the times indicated. Fifteen Wg of total RNA
was hybridized with a cDNA probe for human VEGF. Hybrid-
ization patterns of cells treated with TGF-L1 for 0 min (lane
1); 30 min (lane 2); 1 h (lane 3); 2 h (lane 4); 3 h (lane 5); 4 h
(lane 6); 5 h (lane 7); 6 h (lane 8); are shown. Ethidium bro-
mide staining pattern of 28S and 18S ribosomal RNA bands
are shown in the lower panel. The intensity of VEGF band was
quantitated by image analysis. Fold induction was calculated by
comparing with the VEGF level in untreated cells.
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1 sites [33]. Curcumin [34], an inhibitor of AP-1, was
also tested. Fig. 5 shows that preincubation of cells
with curcumin blocks the induction of VEGF
mRNA (lane 4).
To characterize the transcription factors that were
activated by TGF-L1 treatment, EMSA was per-
formed on nuclear extracts prepared from MC3T3-
E1 cultures treated with or without TGF-L1. Fig. 6
shows that both AP-1 and NF-UB were activated by
TGF-L1 in a time-dependent manner. The optimal
activity was observed at 15 min after stimulation.
The speci¢city of binding was demonstrated by the
Fig. 8. RT-PCR analysis of the expression of VEGF tran-
scripts. RT-PCR was performed as described in Section 2. Con-
trol and TGF-L1-treated RNA are presented in lanes 1 and 2,
respectively. Lane 3 shows the 100-bp DNA ladder. Two
VEGF transcripts of 493 and 626 bp are detected.
Fig. 7. Stimulation of VEGF promoter activity by TGF-L1.
MC3T3-E1 cultures in 60-mm plates were transfected with 2 Wg
of promoterless luciferase gene or luciferase gene containing
VEGF promoter and 5 Wl of FuGene 6 transfection reagent as
described in Section 2. Luciferase activity in the cell lysates was
expressed as light units U103/Wg protein. Results were expressed
as mean þ S.E.M. of three plates for each variable. Statistical
analysis was made by Student’s t-test. aP6 0.05 vs. control
(promoter less), bP6 0.05 vs. control (VEGF promoter).
Fig. 6. TGF-L1 induced activation of AP-1 and NF-UB binding.
Nuclear extracts from control and TGF-L1 (5 ng/ml) treated
MC3T3-E1 cells were incubated with labeled oligomer contain-
ing an AP-1 binding site (top panel) or an NF-UB binding site
(bottom panel). Gel shift patterns of nuclear extract from con-
trol cells (lane 1); cells treated with TGF-L1 for 15 min (lane
2); and cells treated with TGF-L1 for 30 min (lane 3); are
shown. Lanes 4^6 represent the binding pattern of the same
samples in the presence of 100-fold excess cold oligomer.
Fig. 5. E¡ect of curcumin on the induction of VEGF mRNA
by TGF-L1. Near con£uent MC3T3-E1 cells were pretreated
with 20 WM curcumin for 30 min before the addition of 5 ng/
ml TGF-L1 for 2 h. Hybridization patterns of control cells
(lane 1); cells treated with TGF-L1 (lane 2); 20 WM curcumin
(lane 3); TGF-L1 and curcumin (lane 4); are shown.
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disappearance of bands after the addition of excess
unlabeled oligomers (lanes 4^6).
In order to examine whether the induction of
VEGF mRNA is a result of transcriptional activa-
tion, transfection experiments were carried out with a
construct containing VEGF promoter and luciferase
in the absence or presence of TGF-L1. Fig. 7 shows
that TGF-L1 increased luciferase activity of VEGF
gene 3.6-fold, whereas it had no e¡ect on the lucif-
erase gene itself.
Although only a 3.7-kb VEGF mRNA was de-
tected by the Northern blot analysis, RT-PCR ex-
periment revealed two subtypes of mRNA 493 and
626 bp in length in MC3T3-E1 cells (Fig. 8, lane 1).
These two products were enhanced in the presence of
TGF-L1 (lane 2). The sizes of the mRNA match
murine VEGF 120 and VEGF 164 [35].
In order to examine whether the increase of VEGF
mRNA correlated well with the appearance of
VEGF in the conditioned medium, immunoblot
analysis was carried out. The conditioned media of
control and TGF-L1-treated cells were precipitated
by quinine sulfate^SDS. In the absence of TGF-L1,
MC3T3-E1 cells secreted only trace amounts of
VEGF (Fig. 9, lane 1). A protein band of 42 kDa
appeared in the medium 4 h after the addition of
TGF-L1 (lane 2). At 8 h, another 45-kDa band
also appeared (lane 4). The level of these two bands
was increased at 12 h (lane 6), whereas the basal
levels remained low (lanes 3 and 5).
4. Discussion
The present study demonstrates that TGF-L1 acts
on mouse osteoblast MC3T3-E1 cells to induce
VEGF mRNA in a dose- and time-dependent man-
ner. The induction involves a PKC-dependent path-
way. In addition, the increase of VEGF mRNA cor-
relates well with the release of VEGF into the
conditioned medium. The e¡ect of TGF-L1 is not
unique to murine osteoblasts, similar induction was
observed in human osteosarcoma MG-63 cells (C.C.
Chua, R.C. Hamdy and B.H.L. Chua, unpublished
data).
It is interesting that VEGF mRNA is ‘superin-
duced’ in the presence of cycloheximide and TGF-
L1, indicating that de novo synthesis of protein fac-
tors is not necessary for the induction. This could be
due to cycloheximide inhibiting the synthesis of ei-
ther labile ribonucleases involved in degrading
VEGF mRNA, or repressor protein(s) involved in
the regulation of VEGF gene expression. Our data
demonstrated that the induction of VEGF mRNA
level by TGF-L1 could be mainly attributed to tran-
scriptional activation. Electrophoretic mobility shift
assay showed that TGF-L1 enhanced AP-1 and NF-
UB binding. The promoter of mouse VEGF gene has
been shown to contain NF-UB, AP-1, AP-2 and SP-1
binding sites [33]. The involvement of transcription
factors, such as SP-1 or AP-2, in VEGF induction is
under investigation.
Bone is rich in vascular tissues. Bone endothelial
cells are in close proximity with osteoblasts and os-
teoprogenitor cells [9]. These endothelial cells secrete
various cytokines, growth factors or soluble media-
tors that are crucial for bone remodeling and forma-
tion. Accumulating evidence indicates an important
role of VEGF in bone metabolism. Midy and Plouet
[15] demonstrated that VEGF is chemotactic and
could induce migration and di¡erentiation of osteo-
blasts. Several growth factors, cytokines and calcio-
tropic hormones have been demonstrated to induce
the gene expression of VEGF. Hirada et al. [11] re-
ported that prostaglandin E2 and E1 could upregu-
late VEGF at both mRNA and protein level in rat
calvaria-derived osteoblasts. The induction could be
blocked by dexamethasone. Goad et al. [12] demon-
strated that the addition of physiological level of in-
sulin-like growth factor-1 (10 nM) resulted in a four-
fold stimulation of mRNA level in both human
SaOS-2 osteoblast-like cells and primary murine os-
teoblasts. The induction of VEGF mRNA was ac-
Fig. 9. Appearance of VEGF in the conditioned medium of
MC3T3-E1 cells. Cells were treated with or without 5 ng/ml
TGF-L1 for di¡erent times and the conditioned medium was
precipitated with quinine sulfate^SDS. Proteins were separated
by 10% SDS^PAGE. Immunoblot was carried out with rabbit
anti-human VEGF antibodies. Immunostaining patterns of cells
treated with TGF-L1 for 4, 8 and 12 h (lanes 2, 4 and 6) and
their corresponding controls (lanes 1, 3 and 5), are shown.
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companied by an increase in immunoreactive VEGF
protein. In addition, Wang et al. [13] showed that
1,25-dihydroxyvitamin D3 (10311^10310M) could up-
regulate VEGF mRNA level by 1.7- and 2.3-fold in
human osteoblast-like cells (HobLC) and human os-
teosarcoma SaOS-2 cells, respectively. There is a
two-fold increase in the immunoreactive VEGF in
the conditioned medium. Schlaeppi et al. [14] also
found that 1,25-dihydroxyvitamin D3 (1^10 nM)
could stimulate VEGF mRNA expression by approx-
imately three-fold in human osteoblast-like cells. The
up-regulation of VEGF protein was detected after 6 h
of treatment. Combined treatment of parathyroid
hormone (PTH-1^34) and 1,25-dihydroxyvitamin
D3 resulted in approximately ¢ve-fold stimulation
of VEGF mRNA.
The pathophysiological role of VEGF in bone dis-
eases has recently been investigated. Gerber and col-
leagues found high levels of VEGF mRNA expres-
sion in terminal hypertrophic and relatively ischemic
chondrocytes [36]. These investigators have also
shown that VEGF stimulates endochondral bone
formation by inducing capillary invasion of the car-
tilagenous growth plate and by recruiting chondro-
clasts to resorb the apoptotic hypertrophied chon-
drocytes. Steibrech and colleagues reported that
hypoxia during fracture healing was a stimulus for
the osteoblasts to increase the expression of VEGF
and thus enhance the healing process [17]. Our re-
sults demonstrate that TGF-L1 could regulate the
expression of VEGF by the osteoblasts in the ab-
sence of hypoxia.
TGF-L1 has been classi¢ed as an indirect angio-
genic factor, because it stimulates angiogenesis by
facilitating capillary formation in vivo [37], but fails
to stimulate the mitogenic activity and migration of
endothelial cells in vitro [38]. The present study
clearly shows that a direct angiogenic factor VEGF
could be regulated by TGF-L1. A similar phenomen-
on has been observed in smooth muscle cells where
TGF-L1 stimulates the gene expression of two direct
angiogenic factors, VEGF and basic FGF [39].
In summary, we found that TGF-L1 upregulated
the gene expression of VEGF in murine osteoblasts.
The elevated production of VEGF could act on
neighboring endothelial cells and lead to prolifera-
tion and increased blood supply, contributing to
bone formation, remodeling and repair.
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